Christopher K Cote Selected Research

Christopher K Cote Research Topics

14	Infections 02/2021 - 02/2004
9	Plague (Bubonic Plague) 10/2021 - 10/2010
6	Melioidosis 01/2021 - 01/2018
5	Glanders 06/2021 - 01/2016
5	Tularemia 01/2021 - 01/2017
4	Anthrax 01/2021 - 10/2015
2	Bacterial Infections (Bacterial Infection) 01/2021 - 01/2020
2	Bacteremia 01/2021 - 10/2010
1	Horse Diseases (Horse Disease) 01/2021
1	Meningitis 01/2021
1	Toxemia 01/2021
1	Infertility (Sterility) 01/2018
1	Yersinia Infections 06/2011

13	VaccinesIBA 10/2021 - 07/2012
7	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 10/2010
6	Proteins (Proteins, Gene)FDA Link 01/2015 - 12/2010
5	AerosolsIBA 06/2021 - 06/2011
5	AntigensIBA 01/2020 - 02/2004
3	CytokinesIBA 01/2021 - 12/2010
2	anthrax toxin (anthrax lethal factor)IBA 01/2021 - 01/2020
2	Ciprofloxacin (Cipro)FDA LinkGeneric 01/2021 - 01/2017
2	Monoclonal AntibodiesIBA 08/2020 - 10/2010
2	Attenuated VaccinesIBA 11/2019 - 07/2012
2	Virulence Factors (Pathogenicity Factors)IBA 01/2016 - 12/2011
1	Levofloxacin (Levaquin)FDA Link 01/2021
1	Amodiaquine (Camoquin)FDA Link 01/2021
1	ezrinIBA 01/2021
1	InflammasomesIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Plague VaccineIBA 01/2021
1	Clindamycin (Cleocin)FDA LinkGeneric 01/2021
1	Recombinant Fusion ProteinsIBA 01/2021
1	SteamIBA 01/2021
1	Adenosine Monophosphate (AMP)IBA 02/2020
1	Antimicrobial PeptidesIBA 02/2020
1	FluoroquinolonesIBA 01/2020
1	AminoglycosidesIBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020
1	1,2-dehydrosalsolinolIBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2017
1	AcidsIBA 01/2017
1	Immunoglobulin G (IgG)IBA 01/2016
1	Anthrax Vaccines (Vaccines, Anthrax)IBA 10/2015
1	CollagenIBA 01/2015
1	CalciumIBA 01/2014
1	Capsules (Microcapsules)IBA 01/2014
1	Adenosine Triphosphatases (ATPase)IBA 07/2012

6	Therapeutics 10/2021 - 01/2017
1	Duration of Therapy 01/2021